Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XP-3924 vs Regular Insulin and Co-administration in T1D
NCT04074317Phase 2Completed
- Sponsor
- Xeris Biopharma Holdings, Inc.
- Start
- Aug 2019
- Primary completion
- Apr 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of XP-3924 in type 1 diabetes mellitus (T1D) (6 arms), sponsored by Xeris Biopharma Holdings, Inc. Primary endpoint: Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL. Started Aug 2019; status: completed.
02
Drugs
XP-3924
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04074317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074317.